NASDAQ:ORTX Orchard Therapeutics (ORTX) Stock Forecast, Price & News $5.10 +0.12 (+2.41%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$4.91▼$5.1850-Day Range$4.68▼$5.8352-Week Range$3.60▼$7.20Volume18,595 shsAverage Volume64,621 shsMarket Capitalization$93.84 millionP/E RatioN/ADividend YieldN/APrice Target$26.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Orchard Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside409.8% Upside$26.00 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.20Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.96) to ($2.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector215th out of 983 stocksBiological Products, Except Diagnostic Industry27th out of 164 stocks 3.5 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.00, Orchard Therapeutics has a forecasted upside of 409.8% from its current price of $5.10.Amount of Analyst CoverageOrchard Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.46% of the float of Orchard Therapeutics has been sold short.Short Interest Ratio / Days to CoverOrchard Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orchard Therapeutics has recently decreased by 25.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORTX. Previous Next 2.1 News and Social Media Coverage News SentimentOrchard Therapeutics has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Orchard Therapeutics this week, compared to 7 articles on an average week.Search Interest8 people have searched for ORTX on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows2 people have added Orchard Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.34% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by Institutions44.08% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($4.96) to ($2.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Orchard Therapeutics (NASDAQ:ORTX) StockOrchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.Read More Receive ORTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ORTX Stock News HeadlinesJune 1, 2023 | bizjournals.comProvidence Farm Collective buys 37 acres in Orchard ParkMay 31, 2023 | msn.comFlower baskets placed throughout Indian Orchard streetsJune 3, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 31, 2023 | msn.comOrchard Beach in the Bronx non-stop busy for Memorial Day despite cold water temperaturesMay 31, 2023 | msn.comSpringfield firefighters called to fire on Oak St. in Indian OrchardMay 31, 2023 | msn.comAugusta firetruck gets stuck in sinkhole on Peach Orchard RoadMay 30, 2023 | msn.comAugusta firetruck stuck in sinkhole on Peach Orchard RoadMay 29, 2023 | news.yahoo.comOrchard Beach non-stop busy for Memorial DayJune 3, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 26, 2023 | msn.comPlans for Orchard Mesa PoolMay 24, 2023 | finance.yahoo.comOrchard Therapeutics to Present at Stifel’s Genetic Medicines DayMay 24, 2023 | news.yahoo.comSt. Mary's Polish Country Fair may be discontinued permanently in Orchard LakeMay 22, 2023 | news.yahoo.comPerfect for picking: Reid's Orchard hosts 'Strawberry Bliss Market Day'May 21, 2023 | msn.comSpring Clean Up takes place at Bismarck Community OrchardMay 21, 2023 | americanbankingnews.comCantor Fitzgerald Equities Analysts Increase Earnings Estimates for Orchard Therapeutics plc (NASDAQ:ORTX)May 19, 2023 | msn.comAround the Corner: Strawberry Festival at Rivercrest OrchardMay 19, 2023 | msn.comOrchard Therapeutics updates gene therapy data in metabolic disordersMay 18, 2023 | finance.yahoo.comOrchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger IndicationsMay 17, 2023 | americanbankingnews.comOrchard Therapeutics (NASDAQ:ORTX) Issues Quarterly Earnings Results, Beats Estimates By $1.49 EPSMay 17, 2023 | americanbankingnews.comCantor Fitzgerald Reaffirms "Overweight" Rating for Orchard Therapeutics (NASDAQ:ORTX)May 17, 2023 | americanbankingnews.comOrchard Therapeutics plc to Post FY2023 Earnings of ($6.25) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:ORTX)May 17, 2023 | americanbankingnews.comOrchard Therapeutics (NASDAQ:ORTX) Stock Rating Reaffirmed by Cantor FitzgeraldMay 16, 2023 | msn.comOrchard Park students endorse candidates amid heated school board raceMay 16, 2023 | finance.yahoo.comOrchard Therapeutics First Quarter 2023 Earnings: EPS Beats Expectations, Revenues LagMay 15, 2023 | sports.yahoo.comTwo people suffer cuts in Old Orchard BeachMay 15, 2023 | msn.comOrchard Therapeutics GAAP EPS of -$0.12, revenue of $1.23MMay 15, 2023 | finance.yahoo.comOrchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDASee More Headlines ORTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORTX Company Calendar Last Earnings5/15/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORTX CUSIPN/A CIK1748907 Webwww.orchard-tx.com Phone442038088286FaxN/AEmployees259Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.00 High Stock Price Forecast$37.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+409.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($8.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,660,000.00 Net Margins-673.87% Pretax Margin-687.17% Return on Equity-105.36% Return on Assets-53.29% Debt Debt-to-Equity Ratio0.20 Current Ratio3.12 Quick Ratio3.12 Sales & Book Value Annual Sales$22.66 million Price / Sales4.14 Cash FlowN/A Price / Cash FlowN/A Book Value$5.53 per share Price / Book0.92Miscellaneous Outstanding Shares18,400,000Free Float17,784,000Market Cap$93.84 million OptionableNot Optionable Beta0.91 Key ExecutivesBobby GasparChief Executive Officer & Executive DirectorFrank E. ThomasPresident, Chief Operating Officer & CFOLeslie MeltzerChief Medical OfficerNicoletta LoggiaChief Technical OfficerFulvio MavilioChief Scientific OfficerKey CompetitorsCompugenNASDAQ:CGENJATT AcquisitionNYSE:JATTIN8bioNASDAQ:INABPrecision BioSciencesNASDAQ:DTILJounce TherapeuticsNASDAQ:JNCEView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Sold 168,941 shares on 5/18/2023Ownership: 0.262%Temasek Holdings Private LtdSold 3,887,145 shares on 5/15/2023Ownership: 2.348%Platinum Investment Management Ltd.Bought 119,128 shares on 5/12/2023Ownership: 0.648%Renaissance Technologies LLCSold 1,751,162 shares on 5/12/2023Ownership: 0.495%Forefront Analytics LLCSold 150,240 shares on 5/12/2023Ownership: 0.080%View All Institutional Transactions ORTX Stock - Frequently Asked Questions Should I buy or sell Orchard Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORTX shares. View ORTX analyst ratings or view top-rated stocks. What is Orchard Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month price objectives for Orchard Therapeutics' shares. Their ORTX share price forecasts range from $15.00 to $37.00. On average, they anticipate the company's stock price to reach $26.00 in the next year. This suggests a possible upside of 409.8% from the stock's current price. View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts. How have ORTX shares performed in 2023? Orchard Therapeutics' stock was trading at $3.71 at the start of the year. Since then, ORTX shares have increased by 37.5% and is now trading at $5.10. View the best growth stocks for 2023 here. Are investors shorting Orchard Therapeutics? Orchard Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 80,600 shares, a decrease of 25.4% from the April 30th total of 108,100 shares. Based on an average trading volume of 72,600 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.5% of the company's stock are sold short. View Orchard Therapeutics' Short Interest. When is Orchard Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our ORTX earnings forecast. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($1.61) by $1.49. The company had revenue of $1.24 million for the quarter, compared to analysts' expectations of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 105.36% and a negative net margin of 673.87%. When did Orchard Therapeutics' stock split? Orchard Therapeutics shares reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV). When did Orchard Therapeutics IPO? (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Orchard Therapeutics' stock symbol? Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX." Who are Orchard Therapeutics' major shareholders? Orchard Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (10.46%), CHI Advisors LLC (4.27%), Temasek Holdings Private Ltd (2.35%), Citigroup Inc. (0.91%), Acadian Asset Management LLC (0.65%) and Platinum Investment Management Ltd. (0.65%). Insiders that own company stock include Bobby Gaspar, Fmr Llc and Frank E Thomas. View institutional ownership trends. How do I buy shares of Orchard Therapeutics? Shares of ORTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Orchard Therapeutics' stock price today? One share of ORTX stock can currently be purchased for approximately $5.10. How much money does Orchard Therapeutics make? Orchard Therapeutics (NASDAQ:ORTX) has a market capitalization of $93.84 million and generates $22.66 million in revenue each year. The company earns $-150,660,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. How many employees does Orchard Therapeutics have? The company employs 259 workers across the globe. How can I contact Orchard Therapeutics? Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The official website for the company is www.orchard-tx.com. The company can be reached via phone at 442038088286 or via email at investors@orchard-tx.com. This page (NASDAQ:ORTX) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchard Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.